SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gujarat Themis Biosyn reports 36% rise in Q2 net profit

07 Nov 2022 Evaluate

Gujarat Themis Biosyn reported results for second quarter ended September 30, 2022.

The company has reported rise of 35.61% in its net profit at Rs 18.70 crore for Q2FY23 as compared to Rs 13.79 crore for the corresponding quarter previous year. Total income of the company increased by 37.28% to Rs 49.09 crore for the quarter under review as compared to Rs 35.76 crore for the same quarter in the previous year.

Gujarat Themis Biosyn Incorporated in 1981 as a joint sector company with GIIC and Chemosyn Commenced production in August, 1985 by producing Erythromycin and Erythromycin salts and formulations. The Company was taken over during June 1991 by Pharmaceutical Business Group.

Guj. Themis Biosyn Share Price

319.45 15.45 (5.08%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×